Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 2
2009 5
2010 18
2011 11
2012 3
2013 5
2014 3
2015 6
2016 4
2017 3
2018 7
2019 8
2020 12
2021 6
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean samanta kumar pal (1 results)?
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.
Targeting HER2 Epitopes.
Pal SK, Pegram M. Pal SK, et al. Semin Oncol. 2006 Aug;33(4):386-91. doi: 10.1053/j.seminoncol.2006.04.004. Semin Oncol. 2006. PMID: 16890794 Review.
Editorial Comment.
Salgia NJ, Pal SK. Salgia NJ, et al. Among authors: pal sk. J Urol. 2019 Mar;201(3):548. doi: 10.1097/01.JU.0000553713.64297.bb. J Urol. 2019. PMID: 30759699 No abstract available.
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma.
Maia MC, Dizman N, Salgia M, Pal SK. Maia MC, et al. Among authors: pal sk. Kidney Cancer. 2017 Jul 26;1(1):15-29. doi: 10.3233/KCA-170006. Kidney Cancer. 2017. PMID: 30334001 Free PMC article. Review.
Patient-reported Outcome Measures in Metastatic Urinary Cancers.
Bergerot CD, Bergerot PG, Philip EJ, Pal SK. Bergerot CD, et al. Among authors: pal sk. Eur Urol Focus. 2020 Jan 15;6(1):26-30. doi: 10.1016/j.euf.2019.02.020. Epub 2019 Mar 8. Eur Urol Focus. 2020. PMID: 30858072 Review.
Papillary carcinoma of the breast: an overview.
Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G. Pal SK, et al. Breast Cancer Res Treat. 2010 Aug;122(3):637-45. doi: 10.1007/s10549-010-0961-5. Epub 2010 Jun 4. Breast Cancer Res Treat. 2010. PMID: 20524058 Free PMC article. Review.
Current clinical challenges in prostate cancer.
Silberstein JL, Pal SK, Lewis B, Sartor O. Silberstein JL, et al. Among authors: pal sk. Transl Androl Urol. 2013 Sep;2(3):122-36. doi: 10.3978/j.issn.2223-4683.2013.09.03. Transl Androl Urol. 2013. PMID: 26816735 Free PMC article. Review.
The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. Bergerot PG, et al. Among authors: pal sk. Curr Treat Options Oncol. 2018 Feb 20;19(2):10. doi: 10.1007/s11864-018-0530-4. Curr Treat Options Oncol. 2018. PMID: 29464405 Review.
85 results